UroGen officer plans sale of 5,000 shares

UroGen Pharma officer Mark Schoenberg files to sell 5,000 RSU-vested shares under Rule 144 following earlier tax-withholding sales.

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) has a Form 144 notice indicating that officer Mark Schoenberg may sell up to 5,000 ordinary shares of UroGen Pharma Ltd. These shares were issued on September 8, 2026 upon vesting of restricted stock units and involve no cash consideration to him.

The planned sale is through Oppenheimer & Co. Inc. The notice also reports that Schoenberg sold 5,222 ordinary shares on June 8, 2026 for $142,560.60, with the remark that those shares were sold to cover tax withholding obligations upon vesting of equity awards.

Key Figures

Planned shares to be sold: 5,000 ordinary shares Date shares to be sold were issued: September 8, 2026 Prior shares sold: 5,222 ordinary shares +2 more

5 metrics

Planned shares to be sold 5,000 ordinary shares Maximum number of UroGen Pharma Ltd. shares in the Form 144 notice

Date shares to be sold were issued September 8, 2026 Issuance date of shares from RSU vesting

Prior shares sold 5,222 ordinary shares Shares sold by Mark Schoenberg on June 8, 2026

Value of prior sale $142,560.60 Aggregate sale price for 5,222 ordinary shares on June 8, 2026

Purpose of prior sale Tax withholding obligations Remarks state prior sale covered tax withholding on equity award vesting

Key Terms

Rule 144, restricted stock units, equity awards, tax withholding obligations

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"Shares issued upon vesting of RSUs."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

equity awards financial

"Vesting of equity awards."

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

tax withholding obligations financial

"Shares sold to cover tax withholding obligations upon vesting of equity awards."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does UroGen Pharma (URGN) report in this Form 144 filing?

The filing reports that officer Mark Schoenberg intends to sell up to 5,000 ordinary shares of UroGen Pharma Ltd. under Rule 144. These shares were issued on September 8, 2026 upon vesting of restricted stock units for no cash consideration.

How many UroGen Pharma (URGN) shares is Mark Schoenberg planning to sell?

Mark Schoenberg plans to sell up to 5,000 ordinary shares of UroGen Pharma Ltd. The shares were issued upon vesting of RSUs on September 8, 2026, and the Form 144 identifies Oppenheimer & Co. Inc. as the broker.

What prior UroGen Pharma (URGN) share sales are disclosed in the Form 144?

The notice discloses that on June 8, 2026 Mark Schoenberg sold 5,222 ordinary shares of UroGen Pharma Ltd. for $142,560.60. The remarks state these shares were sold to cover tax withholding obligations upon vesting of equity awards.

Were the UroGen Pharma (URGN) shares in this Form 144 purchased for cash?

No. The Form 144 states that the 5,000 ordinary shares to be sold were issued on September 8, 2026 as shares issued upon vesting of RSUs with no consideration, meaning they arose from equity compensation rather than a cash purchase.

Which broker is handling the potential UroGen Pharma (URGN) share sale?

The Form 144 lists Oppenheimer & Co. Inc. as the broker for the potential sale of 5,000 ordinary shares of UroGen Pharma Ltd. by officer Mark Schoenberg in connection with shares issued upon vesting of RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 07:35 AM EDT Accepted by SEC EDGAR 09/09/2026 - 07:34 AM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001763581
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	UroGen Pharma Ltd.
SEC File Number	001-38079
Address of Issuer	9 HA'TA'ASIYA ST RA'ANANA, ISRAEL 4365007
Phone	972 9 770 7601
Name of Person for Whose Account the Securities are To Be Sold	Mark Schoenberg
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares	Oppenheimer & Co. Inc. 85 Broad St. New York NY 10004	871	38402.39	48721701	09/08/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares	09/08/2026	Shares issued upon vesting of RSUs	UroGen Pharma Ltd.			5000	09/08/2026	No consideration, shares issued upon vesting of RSUs

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Schoenberg 9 HA'TA'ASIYA ST RA'ANANA, L3 4365007	Ordinary shares	06/08/2026	5222	142560.60

144: Remarks and Signature

Remarks	Shares sold to cover tax withholding obligations upon vesting of equity awards.
Date of Notice	09/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Mark Schoenberg By: /s/ Meirav Shemesh Title: Authorized Signatory, Oppenheimer Israel (pursuant to delegation)
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)